Rabies - Pipeline Review, H1 2020

  • Life Sciences
  • 30 April 2020
  • 96 Pages
  • Formats:    
  • Report Code: 24WT-3571

Rabies Pipeline Review H1 - Overview

Rabies - Pipeline Review, H1 2020

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rabies - Pipeline Review, H1 2020, provides an overview of the Rabies (Infectious Disease) pipeline landscape.

Rabies is a deadly virus spread to people from the saliva of infected animals. The rabies virus is usually transmitted through a bite. Symptoms include loss of feeling in an area of the body, loss of muscle function, swallowing difficult, excitability, fever and convulsions. The predisposing factors include exposure to wildlife and exposure to other pets that may not be vaccinated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rabies - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rabies (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rabies (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rabies and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 8, 3, 5, 1, 10 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 6 and 1 molecules, respectively.

Rabies (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rabies (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Rabies (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rabies (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rabies (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rabies (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rabies (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rabies (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rabies - Overview
Rabies - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Rabies - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Rabies - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Cadila Healthcare Ltd
Changchun Bcht Biotechnology Co Ltd
Chengdu Rongsheng Pharmaceutical Co Ltd
Chongqing Zhifei Biological Products Co Ltd
CPL Biologicals Pvt Ltd
Curevac AG
GlaxoSmithKline Plc
Humabs BioMed SA
Indian Immunologicals Ltd
Mid-Atlantic BioTherapeutics, Inc.
Molecular Targeting Technologies Inc
NanoViricides Inc
Sanofi
Shandong Yidu Biotechnology Co Ltd
Shanghai Qingsai Biotechnology Co Ltd
Synermore Biologics Co Ltd
Trellis Bioscience Inc
Univercells SA
Yisheng Biopharma Co Ltd
Rabies - Drug Profiles
(Lassa fever + rabies) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Rabies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1014 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNSP-333S1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-7202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-8102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-3903133A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMT-504 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies for Rabies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Glycoprotein for Rabies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Target Glycoprotein for Rabies - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nadorameran - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Niprab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RabiCide-I - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies immune globulin (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rabies vaccine 1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RVC-20 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RVC-58 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SO-57 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOJB - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYN-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VerorabVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VRVg-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Rabies - Dormant Projects
Rabies - Product Development Milestones
Featured News & Press Releases
Jan 07, 2020: CureVac announces positive results in low dose - 1 µg - Rabies vaccine clinical phase 1 study
Sep 03, 2019: Zydus to launch novel biologic for rabies, Twinrab
Jul 22, 2019: Yisheng Biopharma receives GMP certification from China NMPA for production of lyophilized rabies vaccine for preventive use
Oct 23, 2018: CureVac announces first study participant enrolled in Phase I clinical trial testing prophylactic mRNA
Oct 08, 2018: Yisheng Biopharma announces clearance from China FDA to proceed with PIKA rabies vaccine clinical study
Jul 26, 2017: CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine
Jun 30, 2017: SYN023, Synermore’s human rabies immunoglobulin antibody drug received IND approval from CFDA for the Clinical Phase I trial study
Jan 11, 2017: CureVac Provides Clinical Update on CV7201 at 35th Annual J.P. Morgan Healthcare Conference
Jan 04, 2017: US FDA Grants Orphan Drug Designation to Yisheng Biopharma's PIKA Rabies Vaccine
Jan 04, 2016: Yisheng Biopharma Announces Positive Results of Phase I Clinical Trial of a Novel Rabies Vaccine with PIKA Adjuvant
Jul 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to CFDA for the Clinical Phase I trial study
May 31, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug received IND approval from FDA for the Clinical Phase I trial study
Apr 30, 2015: SYN023, Synermore's human rabies immunoglobulin antibody drug submitted IND application to FDA for the Clinical Phase I trial study
Mar 23, 2015: Yisheng Biopharma develops new therapeutic vaccine for rabies
Mar 16, 2015: A new therapeutic vaccine successfully developed against rabies
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables

Number of Products under Development for Rabies, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Rabies - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020

Rabies - Pipeline by Cadila Healthcare Ltd, H1 2020

Rabies - Pipeline by Changchun Bcht Biotechnology Co Ltd, H1 2020

Rabies - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, H1 2020

Rabies - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020

Rabies - Pipeline by CPL Biologicals Pvt Ltd, H1 2020

Rabies - Pipeline by Curevac AG, H1 2020

Rabies - Pipeline by GlaxoSmithKline Plc, H1 2020

Rabies - Pipeline by Humabs BioMed SA, H1 2020

Rabies - Pipeline by Indian Immunologicals Ltd, H1 2020

Rabies - Pipeline by Mid-Atlantic BioTherapeutics, Inc., H1 2020

Rabies - Pipeline by Molecular Targeting Technologies Inc, H1 2020

Rabies - Pipeline by NanoViricides Inc, H1 2020

Rabies - Pipeline by Sanofi, H1 2020

Rabies - Pipeline by Shandong Yidu Biotechnology Co Ltd, H1 2020

Rabies - Pipeline by Shanghai Qingsai Biotechnology Co Ltd, H1 2020

Rabies - Pipeline by Synermore Biologics Co Ltd, H1 2020

Rabies - Pipeline by Trellis Bioscience Inc, H1 2020

Rabies - Pipeline by Univercells SA, H1 2020

Rabies - Pipeline by Yisheng Biopharma Co Ltd, H1 2020

Rabies - Dormant Projects, H1 2020List of Figures

Number of Products under Development for Rabies, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Targets, H1 2020

Number of Products by Stage and Targets, H1 2020

Number of Products by Mechanism of Actions, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020
CHOOSE YOUR BUYING OPTION

NEED A HELP?

Submit your research need or query below

+91 9169162030 (Asia)
help@primemarketreports.com